AustralieFrV1, PascalFrancis, Curation, bibRecord, 000D71

Preparation and characterization of new WHO reference reagents for human chorionic gonadotropin and metabolites

Identifieur interne : 000D71 ( PascalFrancis/Curation ); précédent : 000D70; suivant : 000D72

Preparation and characterization of new WHO reference reagents for human chorionic gonadotropin and metabolites

Auteurs : Steven Birken [États-Unis] ; Peter Berger [Autriche] ; Jean-Michel Bidart [France] ; Matthias Weber [Allemagne] ; Adrian Bristow [Royaume-Uni] ; Rob Norman [Australie] ; Catharine Sturgeon [Royaume-Uni] ; Ulf-Hakan Stenman [Finlande]

Source :

Clinical chemistry : (Baltimore, Md.) [ 0009-9147 ] ; 2003.

RBID : Pascal:03-0267511

Descripteurs français

Pascal (Inist)
- HCG, Exploration, Homme, Normalisation, Réactif, Préparation, Phase préanalytique, Métabolite, OMS, Méthode immunologique, Purification, Chromatographie hydrophobe, Chromatographie HPLC, Etalon analytique.
Wicri :
- topic : Homme, Normalisation.

English descriptors

KwdEn :
- Analytical standard, Exploration, HPLC chromatography, Human, Human chorionic gonadotrophin, Hydrophobic chromatography, Immunological method, Metabolite, Pre analytical step, Preparation, Purification, Reagents, Standardization, WHO.

Abstract

Background: The currently used standards for human chorionic gonadotropin (hCG) and its a and β subunits (hCGa and hCGβ) contain substantial amounts of contaminating variants of hCG and other impurities. Furthermore, some partially degraded forms of hCG and its subunits have become of potential clinical importance, e.g., "nicked" forms of hCG (hCGn) and hCGβ (hCGβn), which contain cuts in the peptide backbone between amino acids 44-45 or 47-48 in hCGβ, and a fragment of hCGβ (hCGβcf) consisting of amino acids 6-40 and 55-92 bound together by disulfide bridges. The IFCC appointed a working group with the aim of preparing new standards for hCG and related substances to improve standardization of their immunoassays. Methods: Large amounts of hCG and its subunits as well as of hCGn, hCGβn, and hCGβcf were prepared by previously developed purification methods in combination with hydrophobic interaction chromatography and reversed-phase HPLC. Each preparation was characterized on the basis of amino acid and sequence analyses, carbohydrate composition, and electrophoretic patterns. Immunoassays for relevant contaminating proteins were also performed. Results: The major preparations were homogeneous and free of contaminating proteins. Concentrations of the final preparations were determined by amino acid analysis. Conclusions: Calibrated in substance concentrations (mol/L) based on amino acid analyses, these preparations will facilitate improved standardization of immunoassays for hCG and its metabolites. The six preparations have now been established by the WHO as new 1st Reference Reagents for immunoassays with the following codes: hCG 99/688, hCGβ 99/650, hCGa 99/720, hCGn 99/642, hCGβn 99/692, and hCGβcf 99/708. In contrast to the 3rd International Standard (75/537), the clinically most important Reference Reagent for hCG (99/688) contains no hCGn and negligible amounts of free subunits.

A01	`01`	`1`		`@0 0009-9147`
A02	`01`			`@0 CLCHAU`
A03		`1`		`@0 Clin. chem. : (Baltim. Md.)`
A05				`@2 49`
A06				`@2 1`
A08	`01`	`1`	`ENG`	`@1 Preparation and characterization of new WHO reference reagents for human chorionic gonadotropin and metabolites`
A11	`01`	`1`		`@1 BIRKEN (Steven)`
A11	`02`	`1`		`@1 BERGER (Peter)`
A11	`03`	`1`		`@1 BIDART (Jean-Michel)`
A11	`04`	`1`		`@1 WEBER (Matthias)`
A11	`05`	`1`		`@1 BRISTOW (Adrian)`
A11	`06`	`1`		`@1 NORMAN (Rob)`
A11	`07`	`1`		`@1 STURGEON (Catharine)`
A11	`08`	`1`		`@1 STENMAN (Ulf-Hakan)`
A14	`01`			`@1 College of Physicians and Surgeons of Columbia University @2 New York, NY 10032 @3 USA @Z 1 aut.`
A14	`02`			`@1 Institute for Biomedical Aging Research, Austrian Academy of Sciences @2 6020 Innsbruck @3 AUT @Z 2 aut.`
A14	`03`			`@1 Department of Clinical Biology, Institut Gustave-Roussy @2 94805 Villejuif @3 FRA @Z 3 aut.`
A14	`04`			`@1 Klinikum Grosshadern, University of Munich @2 81377 Munich @3 DEU @Z 4 aut.`
A14	`05`			`@1 National Institute of Biological Standards and Control @2 Potters Bar, Herts EN6 3QG @3 GBR @Z 5 aut.`
A14	`06`			`@1 Reproductive Medicine Unit, Department of Obstetrics and Gynaecology, University of Adelaide, The Queen Elizabeth Hospital @2 Woodville, South Australia 5011 @3 AUS @Z 6 aut.`
A14	`07`			`@1 Department of Clinical Biochemistry, Royal Infirmary @2 Edinburgh EH3 9YW @3 GBR @Z 7 aut.`
A14	`08`			`@1 Department of Clinical Chemistry, Helsinki University Central Hospital @2 Helsinki 00290 @3 FIN @Z 8 aut.`
A20				`@1 144-154`
A21				`@1 2003`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 7603 @5 354000104155200180`
A44				`@0 0000 @1 © 2003 INIST-CNRS. All rights reserved.`
A45				`@0 35 ref.`
A47	`01`	`1`		`@0 03-0267511`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Clinical chemistry : (Baltimore, Md.)`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Background: The currently used standards for human chorionic gonadotropin (hCG) and its a and β subunits (hCGa and hCGβ) contain substantial amounts of contaminating variants of hCG and other impurities. Furthermore, some partially degraded forms of hCG and its subunits have become of potential clinical importance, e.g., "nicked" forms of hCG (hCGn) and hCGβ (hCGβn), which contain cuts in the peptide backbone between amino acids 44-45 or 47-48 in hCGβ, and a fragment of hCGβ (hCGβcf) consisting of amino acids 6-40 and 55-92 bound together by disulfide bridges. The IFCC appointed a working group with the aim of preparing new standards for hCG and related substances to improve standardization of their immunoassays. Methods: Large amounts of hCG and its subunits as well as of hCGn, hCGβn, and hCGβcf were prepared by previously developed purification methods in combination with hydrophobic interaction chromatography and reversed-phase HPLC. Each preparation was characterized on the basis of amino acid and sequence analyses, carbohydrate composition, and electrophoretic patterns. Immunoassays for relevant contaminating proteins were also performed. Results: The major preparations were homogeneous and free of contaminating proteins. Concentrations of the final preparations were determined by amino acid analysis. Conclusions: Calibrated in substance concentrations (mol/L) based on amino acid analyses, these preparations will facilitate improved standardization of immunoassays for hCG and its metabolites. The six preparations have now been established by the WHO as new 1st Reference Reagents for immunoassays with the following codes: hCG 99/688, hCGβ 99/650, hCGa 99/720, hCGn 99/642, hCGβn 99/692, and hCGβcf 99/708. In contrast to the 3rd International Standard (75/537), the clinically most important Reference Reagent for hCG (99/688) contains no hCGn and negligible amounts of free subunits.
C02	`01`	`X`		`@0 002B24O12`
C03	`01`	`X`	`FRE`	`@0 HCG @5 01`
C03	`01`	`X`	`ENG`	`@0 Human chorionic gonadotrophin @5 01`
C03	`01`	`X`	`SPA`	`@0 HCG @5 01`
C03	`02`	`X`	`FRE`	`@0 Exploration @5 02`
C03	`02`	`X`	`ENG`	`@0 Exploration @5 02`
C03	`02`	`X`	`SPA`	`@0 Exploración @5 02`
C03	`03`	`X`	`FRE`	`@0 Homme @5 03`
C03	`03`	`X`	`ENG`	`@0 Human @5 03`
C03	`03`	`X`	`SPA`	`@0 Hombre @5 03`
C03	`04`	`X`	`FRE`	`@0 Normalisation @5 04`
C03	`04`	`X`	`ENG`	`@0 Standardization @5 04`
C03	`04`	`X`	`SPA`	`@0 Normalización @5 04`
C03	`05`	`X`	`FRE`	`@0 Réactif @5 05`
C03	`05`	`X`	`ENG`	`@0 Reagents @5 05`
C03	`05`	`X`	`SPA`	`@0 Reactivo @5 05`
C03	`06`	`X`	`FRE`	`@0 Préparation @5 06`
C03	`06`	`X`	`ENG`	`@0 Preparation @5 06`
C03	`06`	`X`	`SPA`	`@0 Preparación @5 06`
C03	`07`	`X`	`FRE`	`@0 Phase préanalytique @5 07`
C03	`07`	`X`	`ENG`	`@0 Pre analytical step @5 07`
C03	`07`	`X`	`SPA`	`@0 Fase preanalitica @5 07`
C03	`08`	`X`	`FRE`	`@0 Métabolite @5 08`
C03	`08`	`X`	`ENG`	`@0 Metabolite @5 08`
C03	`08`	`X`	`SPA`	`@0 Metabolito @5 08`
C03	`09`	`X`	`FRE`	`@0 OMS @5 09`
C03	`09`	`X`	`ENG`	`@0 WHO @5 09`
C03	`09`	`X`	`SPA`	`@0 OMS @5 09`
C03	`10`	`X`	`FRE`	`@0 Méthode immunologique @5 10`
C03	`10`	`X`	`ENG`	`@0 Immunological method @5 10`
C03	`10`	`X`	`SPA`	`@0 Método inmunológico @5 10`
C03	`11`	`X`	`FRE`	`@0 Purification @5 11`
C03	`11`	`X`	`ENG`	`@0 Purification @5 11`
C03	`11`	`X`	`SPA`	`@0 Purificación @5 11`
C03	`12`	`X`	`FRE`	`@0 Chromatographie hydrophobe @5 12`
C03	`12`	`X`	`ENG`	`@0 Hydrophobic chromatography @5 12`
C03	`12`	`X`	`SPA`	`@0 Cromatografía hidrofóbica @5 12`
C03	`13`	`X`	`FRE`	`@0 Chromatographie HPLC @5 13`
C03	`13`	`X`	`ENG`	`@0 HPLC chromatography @5 13`
C03	`13`	`X`	`SPA`	`@0 Cromatografía HPLC @5 13`
C03	`14`	`X`	`FRE`	`@0 Etalon analytique @5 18`
C03	`14`	`X`	`ENG`	`@0 Analytical standard @5 18`
C03	`14`	`X`	`SPA`	`@0 Patrón analítico @5 18`
C07	`01`	`X`	`FRE`	`@0 Gonadotrophine @5 37`
C07	`01`	`X`	`ENG`	`@0 Gonadotropin @5 37`
C07	`01`	`X`	`SPA`	`@0 Gonadotropina @5 37`
C07	`02`	`X`	`FRE`	`@0 Hormone placentaire @5 38`
C07	`02`	`X`	`ENG`	`@0 Placental hormone @5 38`
C07	`02`	`X`	`SPA`	`@0 Hormona placentaria @5 38`
C07	`03`	`X`	`FRE`	`@0 Hormone glycoprotéine @5 39`
C07	`03`	`X`	`ENG`	`@0 Glycoprotein hormone @5 39`
C07	`03`	`X`	`SPA`	`@0 Hormona glicoproteína @5 39`
C07	`04`	`X`	`FRE`	`@0 Biologie clinique @5 40`
C07	`04`	`X`	`ENG`	`@0 Clinical biology @5 40`
C07	`04`	`X`	`SPA`	`@0 Biología clínica @5 40`
N21				`@1 174`
N82				`@1 PSI`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :005355

Links to Exploration step

Pascal:03-0267511

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Preparation and characterization of new WHO reference reagents for human chorionic gonadotropin and metabolites</title>
<author><name sortKey="Birken, Steven" sort="Birken, Steven" uniqKey="Birken S" first="Steven" last="Birken">Steven Birken</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>College of Physicians and Surgeons of Columbia University</s1>
<s2>New York, NY 10032</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Berger, Peter" sort="Berger, Peter" uniqKey="Berger P" first="Peter" last="Berger">Peter Berger</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute for Biomedical Aging Research, Austrian Academy of Sciences</s1>
<s2>6020 Innsbruck</s2>
<s3>AUT</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Bidart, Jean Michel" sort="Bidart, Jean Michel" uniqKey="Bidart J" first="Jean-Michel" last="Bidart">Jean-Michel Bidart</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Clinical Biology, Institut Gustave-Roussy</s1>
<s2>94805 Villejuif</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Weber, Matthias" sort="Weber, Matthias" uniqKey="Weber M" first="Matthias" last="Weber">Matthias Weber</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Klinikum Grosshadern, University of Munich</s1>
<s2>81377 Munich</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Bristow, Adrian" sort="Bristow, Adrian" uniqKey="Bristow A" first="Adrian" last="Bristow">Adrian Bristow</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>National Institute of Biological Standards and Control</s1>
<s2>Potters Bar, Herts EN6 3QG</s2>
<s3>GBR</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Norman, Rob" sort="Norman, Rob" uniqKey="Norman R" first="Rob" last="Norman">Rob Norman</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Reproductive Medicine Unit, Department of Obstetrics and Gynaecology, University of Adelaide, The Queen Elizabeth Hospital</s1>
<s2>Woodville, South Australia 5011</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Sturgeon, Catharine" sort="Sturgeon, Catharine" uniqKey="Sturgeon C" first="Catharine" last="Sturgeon">Catharine Sturgeon</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Department of Clinical Biochemistry, Royal Infirmary</s1>
<s2>Edinburgh EH3 9YW</s2>
<s3>GBR</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Stenman, Ulf Hakan" sort="Stenman, Ulf Hakan" uniqKey="Stenman U" first="Ulf-Hakan" last="Stenman">Ulf-Hakan Stenman</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Department of Clinical Chemistry, Helsinki University Central Hospital</s1>
<s2>Helsinki 00290</s2>
<s3>FIN</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Finlande</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">03-0267511</idno>
<date when="2003">2003</date>
<idno type="stanalyst">PASCAL 03-0267511 INIST</idno>
<idno type="RBID">Pascal:03-0267511</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">005355</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000D71</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Preparation and characterization of new WHO reference reagents for human chorionic gonadotropin and metabolites</title>
<author><name sortKey="Birken, Steven" sort="Birken, Steven" uniqKey="Birken S" first="Steven" last="Birken">Steven Birken</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>College of Physicians and Surgeons of Columbia University</s1>
<s2>New York, NY 10032</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Berger, Peter" sort="Berger, Peter" uniqKey="Berger P" first="Peter" last="Berger">Peter Berger</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute for Biomedical Aging Research, Austrian Academy of Sciences</s1>
<s2>6020 Innsbruck</s2>
<s3>AUT</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Bidart, Jean Michel" sort="Bidart, Jean Michel" uniqKey="Bidart J" first="Jean-Michel" last="Bidart">Jean-Michel Bidart</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Clinical Biology, Institut Gustave-Roussy</s1>
<s2>94805 Villejuif</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Weber, Matthias" sort="Weber, Matthias" uniqKey="Weber M" first="Matthias" last="Weber">Matthias Weber</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Klinikum Grosshadern, University of Munich</s1>
<s2>81377 Munich</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Bristow, Adrian" sort="Bristow, Adrian" uniqKey="Bristow A" first="Adrian" last="Bristow">Adrian Bristow</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>National Institute of Biological Standards and Control</s1>
<s2>Potters Bar, Herts EN6 3QG</s2>
<s3>GBR</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Norman, Rob" sort="Norman, Rob" uniqKey="Norman R" first="Rob" last="Norman">Rob Norman</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Reproductive Medicine Unit, Department of Obstetrics and Gynaecology, University of Adelaide, The Queen Elizabeth Hospital</s1>
<s2>Woodville, South Australia 5011</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Sturgeon, Catharine" sort="Sturgeon, Catharine" uniqKey="Sturgeon C" first="Catharine" last="Sturgeon">Catharine Sturgeon</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Department of Clinical Biochemistry, Royal Infirmary</s1>
<s2>Edinburgh EH3 9YW</s2>
<s3>GBR</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Stenman, Ulf Hakan" sort="Stenman, Ulf Hakan" uniqKey="Stenman U" first="Ulf-Hakan" last="Stenman">Ulf-Hakan Stenman</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Department of Clinical Chemistry, Helsinki University Central Hospital</s1>
<s2>Helsinki 00290</s2>
<s3>FIN</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Finlande</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Clinical chemistry : (Baltimore, Md.)</title>
<title level="j" type="abbreviated">Clin. chem. : (Baltim. Md.)</title>
<idno type="ISSN">0009-9147</idno>
<imprint><date when="2003">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Clinical chemistry : (Baltimore, Md.)</title>
<title level="j" type="abbreviated">Clin. chem. : (Baltim. Md.)</title>
<idno type="ISSN">0009-9147</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Analytical standard</term>
<term>Exploration</term>
<term>HPLC chromatography</term>
<term>Human</term>
<term>Human chorionic gonadotrophin</term>
<term>Hydrophobic chromatography</term>
<term>Immunological method</term>
<term>Metabolite</term>
<term>Pre analytical step</term>
<term>Preparation</term>
<term>Purification</term>
<term>Reagents</term>
<term>Standardization</term>
<term>WHO</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>HCG</term>
<term>Exploration</term>
<term>Homme</term>
<term>Normalisation</term>
<term>Réactif</term>
<term>Préparation</term>
<term>Phase préanalytique</term>
<term>Métabolite</term>
<term>OMS</term>
<term>Méthode immunologique</term>
<term>Purification</term>
<term>Chromatographie hydrophobe</term>
<term>Chromatographie HPLC</term>
<term>Etalon analytique</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
<term>Normalisation</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background: The currently used standards for human chorionic gonadotropin (hCG) and its a and β subunits (hCGa and hCGβ) contain substantial amounts of contaminating variants of hCG and other impurities. Furthermore, some partially degraded forms of hCG and its subunits have become of potential clinical importance, e.g., "nicked" forms of hCG (hCGn) and hCGβ (hCGβn), which contain cuts in the peptide backbone between amino acids 44-45 or 47-48 in hCGβ, and a fragment of hCGβ (hCGβcf) consisting of amino acids 6-40 and 55-92 bound together by disulfide bridges. The IFCC appointed a working group with the aim of preparing new standards for hCG and related substances to improve standardization of their immunoassays. Methods: Large amounts of hCG and its subunits as well as of hCGn, hCGβn, and hCGβcf were prepared by previously developed purification methods in combination with hydrophobic interaction chromatography and reversed-phase HPLC. Each preparation was characterized on the basis of amino acid and sequence analyses, carbohydrate composition, and electrophoretic patterns. Immunoassays for relevant contaminating proteins were also performed. Results: The major preparations were homogeneous and free of contaminating proteins. Concentrations of the final preparations were determined by amino acid analysis. Conclusions: Calibrated in substance concentrations (mol/L) based on amino acid analyses, these preparations will facilitate improved standardization of immunoassays for hCG and its metabolites. The six preparations have now been established by the WHO as new 1st Reference Reagents for immunoassays with the following codes: hCG 99/688, hCGβ 99/650, hCGa 99/720, hCGn 99/642, hCGβn 99/692, and hCGβcf 99/708. In contrast to the 3rd International Standard (75/537), the clinically most important Reference Reagent for hCG (99/688) contains no hCGn and negligible amounts of free subunits.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0009-9147</s0>
</fA01>
<fA02 i1="01"><s0>CLCHAU</s0>
</fA02>
<fA03 i2="1"><s0>Clin. chem. : (Baltim. Md.)</s0>
</fA03>
<fA05><s2>49</s2>
</fA05>
<fA06><s2>1</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Preparation and characterization of new WHO reference reagents for human chorionic gonadotropin and metabolites</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>BIRKEN (Steven)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>BERGER (Peter)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>BIDART (Jean-Michel)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>WEBER (Matthias)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>BRISTOW (Adrian)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>NORMAN (Rob)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>STURGEON (Catharine)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>STENMAN (Ulf-Hakan)</s1>
</fA11>
<fA14 i1="01"><s1>College of Physicians and Surgeons of Columbia University</s1>
<s2>New York, NY 10032</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Institute for Biomedical Aging Research, Austrian Academy of Sciences</s1>
<s2>6020 Innsbruck</s2>
<s3>AUT</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Clinical Biology, Institut Gustave-Roussy</s1>
<s2>94805 Villejuif</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Klinikum Grosshadern, University of Munich</s1>
<s2>81377 Munich</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>National Institute of Biological Standards and Control</s1>
<s2>Potters Bar, Herts EN6 3QG</s2>
<s3>GBR</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Reproductive Medicine Unit, Department of Obstetrics and Gynaecology, University of Adelaide, The Queen Elizabeth Hospital</s1>
<s2>Woodville, South Australia 5011</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Department of Clinical Biochemistry, Royal Infirmary</s1>
<s2>Edinburgh EH3 9YW</s2>
<s3>GBR</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Department of Clinical Chemistry, Helsinki University Central Hospital</s1>
<s2>Helsinki 00290</s2>
<s3>FIN</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA20><s1>144-154</s1>
</fA20>
<fA21><s1>2003</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>7603</s2>
<s5>354000104155200180</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2003 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>35 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>03-0267511</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Clinical chemistry : (Baltimore, Md.)</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Background: The currently used standards for human chorionic gonadotropin (hCG) and its a and β subunits (hCGa and hCGβ) contain substantial amounts of contaminating variants of hCG and other impurities. Furthermore, some partially degraded forms of hCG and its subunits have become of potential clinical importance, e.g., "nicked" forms of hCG (hCGn) and hCGβ (hCGβn), which contain cuts in the peptide backbone between amino acids 44-45 or 47-48 in hCGβ, and a fragment of hCGβ (hCGβcf) consisting of amino acids 6-40 and 55-92 bound together by disulfide bridges. The IFCC appointed a working group with the aim of preparing new standards for hCG and related substances to improve standardization of their immunoassays. Methods: Large amounts of hCG and its subunits as well as of hCGn, hCGβn, and hCGβcf were prepared by previously developed purification methods in combination with hydrophobic interaction chromatography and reversed-phase HPLC. Each preparation was characterized on the basis of amino acid and sequence analyses, carbohydrate composition, and electrophoretic patterns. Immunoassays for relevant contaminating proteins were also performed. Results: The major preparations were homogeneous and free of contaminating proteins. Concentrations of the final preparations were determined by amino acid analysis. Conclusions: Calibrated in substance concentrations (mol/L) based on amino acid analyses, these preparations will facilitate improved standardization of immunoassays for hCG and its metabolites. The six preparations have now been established by the WHO as new 1st Reference Reagents for immunoassays with the following codes: hCG 99/688, hCGβ 99/650, hCGa 99/720, hCGn 99/642, hCGβn 99/692, and hCGβcf 99/708. In contrast to the 3rd International Standard (75/537), the clinically most important Reference Reagent for hCG (99/688) contains no hCGn and negligible amounts of free subunits.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B24O12</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>HCG</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Human chorionic gonadotrophin</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>HCG</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Exploration</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Exploration</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Exploración</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Homme</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Human</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Hombre</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Normalisation</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Standardization</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Normalización</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Réactif</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Reagents</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Reactivo</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Préparation</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Preparation</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Preparación</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Phase préanalytique</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Pre analytical step</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Fase preanalitica</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Métabolite</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Metabolite</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Metabolito</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>OMS</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>WHO</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>OMS</s0>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Méthode immunologique</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Immunological method</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Método inmunológico</s0>
<s5>10</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Purification</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Purification</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Purificación</s0>
<s5>11</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Chromatographie hydrophobe</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Hydrophobic chromatography</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Cromatografía hidrofóbica</s0>
<s5>12</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Chromatographie HPLC</s0>
<s5>13</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>HPLC chromatography</s0>
<s5>13</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Cromatografía HPLC</s0>
<s5>13</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Etalon analytique</s0>
<s5>18</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Analytical standard</s0>
<s5>18</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Patrón analítico</s0>
<s5>18</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Gonadotrophine</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Gonadotropin</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Gonadotropina</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Hormone placentaire</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Placental hormone</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Hormona placentaria</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Hormone glycoprotéine</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Glycoprotein hormone</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Hormona glicoproteína</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Biologie clinique</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Clinical biology</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Biología clínica</s0>
<s5>40</s5>
</fC07>
<fN21><s1>174</s1>
</fN21>
<fN82><s1>PSI</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D71 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000D71 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:03-0267511
   |texte=   Preparation and characterization of new WHO reference reagents for human chorionic gonadotropin and metabolites
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Preparation and characterization of new WHO reference reagents for human chorionic gonadotropin and metabolites

Preparation and characterization of new WHO reference reagents for human chorionic gonadotropin and metabolites

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri